Key terms
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SPRO news
Mar 18
6:26am ET
Spero Therapeutics’ Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating
Mar 15
4:40pm ET
Spero Therapeutics files $300M mixed securities shelf
Mar 13
11:25pm ET
TD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)
Mar 13
4:06pm ET
Spero Therapeutics reports Q4 EPS (96c), consensus (10c)
Mar 05
10:25am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Mar 05
4:55am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Mar 01
12:19pm ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Feb 28
8:12am ET
Spero Therapeutics announces clearance by U.S. FDA of IND for SPR206
Feb 10
4:31am ET
Spero Therapeutics Announces Chief Legal Officer’s Resignation
Jan 05
8:19am ET
Spero Therapeutics expects cash to fund requirements into late 2025
Jan 05
8:19am ET
Spero Therapeutics provides 2024 anticipated milestones
Jan 03
7:45am ET
Spero Therapeutics’ Promising Outlook: Clinical Milestones and Strategic GSK Partnership
Jan 02
8:15am ET
Spero announces first patient, first visit for Phase 3 PIVOT-PO trial
No recent news articles are available for SPRO
No recent press releases are available for SPRO
SPRO Financials
Key terms
Ad Feedback
SPRO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SPRO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range